Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.46 |
| ▸ | TUBB | P07437 | 4/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186201 | 0.90 | CYP1A2 (0.54) | CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL4181140 | 0.86 | CYP1A2 (0.50) | CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL4173392 | 0.86 | ALDH1A1 (0.49) | CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL4179200 | 0.81 | TUBB4A (0.56) | HSD17B10CLK4TUBB4ATUBBTUBA3C | |
| SCHEMBL4180867 | 0.81 | CYP3A4 (0.57) | CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL4170897 | 0.80 | KDR (0.49) | CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL4181716 | 0.80 | TUBB4A (0.68) | CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL4172627 | 0.80 | CYP1A2 (0.66) | CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL4173413 | 0.79 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4166190 | 0.79 | TUBB4A (0.55) | CYP3A4CYP2C19CYP1A2CYP2D6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | CYP3A4 852/4885CYP2C19 1657/4885CYP1A2 1124/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | CYP3A4 852/4885CYP2C19 1657/4885CYP1A2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.